1601-RIG-I Targeting for PANoptosis Cancer Immunotherapy
The research introduces Hemin-His-Mn, a tumor-targeting nanozyme designed to overcome cancer immunotherapy resistance by triggering PANoptosis, a robust form of programmed cell death. This innovative nanomedicine acts by binding to the RIG-I protein, alleviating its autoinhibition to initiate PANoptosome assembly while simultaneously generating lethal reactive oxygen species to accelerate cell destruction. By inducing this immunogenic death, the platform effectively releases danger signals that reprogram the tumor microenvironment and activate a potent T cell-mediated immune response…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.